A Thorough QTc Evaluation of the Effect of Semaglutide on Cardiac Repolarisation in Healthy Subjects

NCT02064348 · Completed

Last updated 2026-05-28

This clinical trial tested the effect of semaglutide, a medication, on heart rhythm in healthy adults and people with diabetes by measuring changes in the QT interval of the heart's electrical activity.

Status Completed The study has finished.

Phase Phase 1 Checks safety and dosing in a small group.

Type Interventional (clinical trial)

Design Randomized, double-blind treatment study

Participants 168 people

Who can join Ages 18–45 · all sexes Healthy volunteers accepted.

Timeline Started 2014-02 · est. completion 2015-04

Where 1 site · Germany

What this study is testing ClinicalTrials.gov NCT02064348 ↗

Description as written by the study sponsor.

This trial is conducted in Europe. The aim of the trial is to evaluate the effect of semaglutide on cardiac repolarisation in healthy subjects.

Treatments tested

semaglutide Drug

Solution for subcutaneous (s.c., under the skin) injection. Dose escalation to 1.5 mg.
placebo Drug

Solution for s.c. injection or tablets for oral administration
moxifloxacin Drug

Tablets for oral administration

Main thing measured	QTcI, (Individual heart rate corrected QT (Interval in the ECG: from the start of the QRS complex to the end) interval) based on ECG recordings obtained at 11 time points
Sponsor	Novo Nordisk A/S
Conditions studied	Diabetes, Healthy
GLP-1 drugs	semaglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT02064348 ↗